Dr. Yaron Pereg Appointed as New Chief Development Officer

TEL AVIV, Israel, Jan. 30, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, today announces that it has appointed Yaron Pereg, Ph.D., as the new Chief Development Officer of the Company filling the role of the recently resigned Dr. Nadir Askenasy, who served as its Chief Technology Officer. Dr. Pereg brings unique experience in large scale biotech projects development from his role as Senior Director of Oncology at BioLineRx.

Cellect CEO, Shai Yarkoni commented, “Yaron is an R&D expert with outstanding experience that can help us take our proprietary technology and science to the next level. He is a strong addition to our growing executive team and will be a vital part of our ability to execute on our business plan.”   

Dr. Pereg has worked at innovative biopharmaceutical companies for over a decade leading worldwide non-clinical and clinical programs of multiple drug development projects, managing multi-disciplinary teams and multi-million dollar budgets. He has a diverse experience in pharma and biotech R&D, including preclinical, regulatory, clinical, CMC and operational activities of drug development in the field of oncology.

Dr. Pereg commented, “I am excited to join Cellect which I believe may become a real game changer in the 21^st century regenerative medicine. I am proud to be a part in building this groundbreaking technology that can change the lives of millions of patients.”

Prior to BioLineRx, Dr. Pereg held research and development positions at Genentech Inc., a leading biotechnology company and member of the Roche Group, and at Glusense, a medical-device start-up company.

About Cellect Biotechnology Ltd.

Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ:APOP) (NASDAQ:APOPW) (TASE:APOP). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue, a technology that aims to improve a variety of stem cells applications.

The Company’s technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stems cell related treatments and procedures. Cellect’s technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.

Forward Looking Statements
This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Cellect Biotechnology Ltd.'s final prospectus dated July 29, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov and in the Company’s period filings with the SEC and the Tel-Aviv Stock Exchange.

Contact
Cellect Biotechnology Ltd. 
Eyal Leibovitz, Chief Financial Officer
www.cellectbio.com
+ 972-9-974-1444

LifeSci Advisors
Bob Yedid, Managing Director
646-597-6989
[email protected]